In the older adult group, all but one of the Grade 3 events were reported by participants in the 300g treatment group: fatigue in 6 (26.1%), myalgia in 1 (4.3%), headache in 4 (17.4%) and malaise in 6 (26.1%), nausea in 1 (4.3%), and chills in 2 (8.7%). Barney Graham, a former scientist at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), was thrilled yesterday when Pfizer announced encouraging results from an experimental vaccine that could protect against a major childhood killer. The subject has a history of narcolepsy. Overall, vaccination with mRNA-1777 (V171) increased RSV A and B serum neutralization GMTs at all doses tested in both the younger and older adults. Single injection of mRNA-1345 and mRNA-1273.214, administered IM, one in each arm on Day 1. With regard to liver function tests at Screening: ALT and AST must be equal to or below 1.5 upper limit of normal (ULN). 902. 7. Existing flu vaccines are only 40% to 60% effective in preventing infection, and sometimes by a flu season's end only 10% effective. Phase 1/2, first-in-human study of the safety, tolerability, and immunogenicity of an RSV prefusion F-based subunit vaccine candidate. Luchsinger V, Piedra PA, Ruiz M, Zunino E, Martinez MA, Machado C, Fasce R, Ulloa MT, Fink MC, Lara P, et al. Percentages were based on the number of participants who received the specified treatment and overall. Each treatment arm consisted of three sentinel participants and expansion cohorts (Figure 2). In Pfizers trial, which is taking place in 18 countries, 7400 pregnant womenreceived one dose of RSVpreF or a placebo shot during their late second or third trimester. mRNA-1345 is a vaccine against RSV developed by Moderna, Inc., November 18, 2021- Moderna, Inc. announced the first participant had been dosed in the ConquerRSV Phase 2/3 study of mRNA-1345, an RSV vaccine candidate. Part A included three sequential treatment arms of 25g, 100g and 200g doses. Data are background subtracted based on the negative control stimulation, which was dimethyl sulfoxide, the diluent used for the peptide pool. Participants received mRNA-1777 (V171) or placebo as a single intramuscular dose. Males and females of non-childbearing potential in good general health between the ages of 18 and 49 (inclusive; Part A) or between 60 and 79years of age (inclusive; Part B) were included. "We can't make a direct comparison. Exception is subjects with adequately treated non-melanomatous skin carcinoma, who may participate in the study. 2. It appears that the only reason Moderna even piloted this new damning study is to market new and additional shots to fix the problem created by the first round of shots. Infants who suffer from severe infections with respiratory syncytial virus, such as this one at a German intensive care unit, often require ventilation. GSK appears to have beaten Pfizer in getting a BLA for its RSV vaccine in front of the FDA, securing priority review for the use of its jab among older adults. Drugs Aging. One hundred percent (100%) of the participants in the 25g, 100g, and 200g groups, 95.7% of the 300g group and 96.3% of the placebo group completed the study (Figure 2). The trial, which involved roughly 25,000 adults aged 60 and over, showed the vaccine was 94.1% effective against severe lower respiratory tract disease associated with an RSV infection, the British drugmaker said. This cookie is set by GDPR Cookie Consent plugin. The subject has a history of Guillain-Barr syndrome. Typically, Big Pharma companies such as Pfizer and Moderna shy away from early-stage R&D on flu vaccines, because historically they generate modest revenues. are employees of Moderna, Inc., Cambridge, MA 02139, USA, and may hold stock in Moderna, Inc., Cambridge, MA 02139, USA. Employees in special suits test the procedures for the manufacturing of the messenger RNA (mRNA) for the Covid-19 vaccine in German company BioNTech, in Marburg, Germany on March 29, 2021. If we've learned anything from the COVID-19 pandemic, it's that we cannot wait for a crisis to respond. 2022 CNBC LLC. Dive Insight: The new GSK data should set a bar for rivals developing an RSV vaccine for older people. The subject has access to consistent and reliable means of telephone contact, which may be in the home, workplace, or by personal mobile electronic device. Moderna is studying mRNA-1345, an investigational vaccine, to understand whether it can help your bodys immune system protect against RSV. Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults. The hunt for an effective way to protect against RSV stalled for decades after two children died in a disastrous vaccine trial in the 1960s. Participants in the mRNA treated group also reported solicited systemic AEs more frequently as compared to placebo. in fact, give people vaccine-induced AIDS (VAIDS), which is basically what this all is. In the older adults, peak GMFI for RSV A was 3.5-fold for the 25g dose group, 4.3-fold for the 100g, 3.0-fold for the 200g group and 3.6-fold for the 300g group (Figure 5(c), Supplemental Table 6). However, covid vaccines are another story altogether. The subject has any known or suspected autoimmune disease or immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination. Taking these limitations into account, results can be generally compared by viewing fold changes in neutralization titers before and after vaccination. Several recombinant protein-based prefusion F investigational vaccines have also been evaluated. Feldman RA, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M, Senn JJ, Smith M, Almarsson O, Pujar HS, et al. In the older adult group overall, the proportion of participants who reported solicited systemic AEs was higher in the 300g treatment group (91.3%) than in the 25g, 100g, 200g and placebo treatment groups (55.6%, 70.8%, 62.5%, and 37.0%, respectively). Its like looking through a mirror darkly type of understanding. So we have a product for flu on the market in the fall of '23. Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by: Absence of changes in medical therapy within 1 month due to treatment failure or toxicity; Absence of medical events qualifying as SAEs within 1 month of the planned vaccination on Day 1; and absence of known, current, and life-limiting diagnoses which, in the opinion of the investigator, would make completion of the protocol unlikely. The site is secure. It does not store any personal data. DCA in the younger adults increased 2.2, 3.7, and 3.7-fold over Day 1 for the 25g, 100g, and 200g groups, respectively at the peak (Day 29) (Figure 7(a)). Grade 3 unsolicited TEAEs were reported by 22.2%, 8.3%, 12.5%, and 8.7% in the 25g, 100g, 200g, and 300g mRNA-1777 (V171) groups, respectively, and 3.7% in the placebo group. Participants with a body mass index (BMI) 18 kg/m2 to 32 kg/m2 were included in the study. The hunt for an effective way to protect against RSV stalled for decades after two children died in a disastrous vaccine trial in the 1960s. Last November, Connecticut Rep. Rosa DeLauro and Massachusetts Sen. Ed Markey reintroduced the Flu Vaccine Act, a bill proposing an investment of $1 billion for the NIH's flu research projects, including external collaborations. The stained plates were scanned using a Li-Cor Aerius (LI-COR Biosciences, Lincoln, Nebraska) infrared fluorescence scanner. The type of vaccine, Moderna or Pfizer, did not change the results. The vaccine also triggered a T cell problem that added to airway obstruction and lack of clearance of the virus. Participant has received or plans to receive any vaccine authorized or approved by a local health agency 28 days prior to study injections (Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections. 20. The mRNA-1777 (V171) vaccine was diluted to the target dose using 0.9% Sodium Chloride Injection, USP or BP as the diluent. It is unknown what the effect of ethnicity or gender is on the immunogenicity or safety due to the size of this study and thus larger and more diverse studies will be required to evaluate the impact of these factors. The hunt for an effective way to protect against RSV stalled for decades after two children died in a disastrous vaccine trial in the 1960s. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. All rights reserved. 11. Subscribe to News from Science for full access to breaking news and analysis on research and science policy. Single injection of mRNA-1345 and Afluria quadrivalent, administered IM, one in each arm on Day 1. single-dose, pre-filled syringe for injection. We want to hear from you. Immunization with mRNA-1777 (V171) elicited a humoral immune response as measured by increases in RSV neutralizing antibody titers, serum antibody titers to RSV prefusion F protein, D25 competing antibody titers to RSV prefusion F protein, and cell-mediated immune responses to RSV-F peptides. Moderna has had a historic rise from a small biotech to a major vaccine player in the past two years. Approximately 1 million cells were stimulated with an RSV F peptide pool and anti-CD28/CD49d antibodies for two hours at 37C followed by four additional hours in the presence of GolgiPlug (BD Biosciences). The 100g and 200g arms each consisted of 24 active and eight placebo, and the 300g arm consisted of 23 active and eight placebo. Study finds possible link between Pfizers COVID-19 vaccine and myocarditis in children. Grahams NIAID group made a similar modification to the SARS-CoV-2 surface protein, spike, which was adopted by Moderna, Pfizer, and other companies in their designs of COVID-19 vaccines. In October last year, Janssen revealed results of its Phase IIb CYPRESS study, touting an 80% vaccine efficacy of its candidate against RSV-LRTD. Josh Sigurdson: COVID-19 vaccines causing cancer rates to skyrocket. All Rights Reserved. A:The vaccine boosts way, way higher than a natural exposure to the live virus. Alkaline phosphatase and direct bilirubin must be equal to or below the ULN. The primary goal of the phase 3 study is to establish whether mRNA-1345 is safe and effective against RSV. Moderna has had a historic rise from a small biotech to a major vaccine player in the past two years. Duncan CB, Walsh EE, Peterson DR, Lee FE, Falsey AR. Normally, vaccines for viruses are made from a weakened or inactive version of the virus. Drug supplies were shipped, stored, and distributed in accordance with the trial protocol. The cells were washed, fixed and incubated with mouse monoclonal antibodies to RSV F and RSV N. The plates were washed and incubated with biotinylated anti-mouse IgG followed by infrared dye-streptavidin to detect the RSV specific signal. The shot did not have a significant impact on infant doctor visits related to respiratory disease: Efficacy was 57.1% at 90 days and 51.3% over 6 months. The mRNA-1777 (V171) vaccine consisted of chemically modified mRNA encoding a full length (membrane-associated) RSV F protein stabilized in the prefusion conformation using the modification described by McLellan et al.17(mDS-Cav1),26 and an LNP delivery system. The subject has any acute illness at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0C on the planned day of dose administration). We also use third-party cookies that help us analyze and understand how you use this website. "mRNA is an information molecule and so we have now forty-four zero programs that are in development and actually many more in the labs.". The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. mRNA-1345 contains the same lipid nanoparticle (LNP) as Modernas COVID-19 vaccine. An MRNA vaccine against SARS-COV-2 - preliminary report. The 300g arm was included as a conditional group to further characterize the relationship between dose, tolerability, and immunogenicity in healthy older adults, and was implemented by the sponsor with approval of the SMC based on the tolerability and immunogenicity observed in the lower dose groups. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus, An overview of respiratory syncytial virus. There is an antibody problem and a T cell problem. RSV treatment in adults is limited to supportive care and general symptom management. Respiratory Syncytial Virus is a non-segmented RNA virus with two subtypes, RSV A and RSV B. An additional injection of mRNA-1273.214, administered as booster dose on Day 29. There are dozens of other flu vaccine R&D projects underway in the U.S., some in search of what are known as supra-seasonal shots that could prevent recipients from becoming infected for several years. Placebo was a matched volume of 0.9% Sodium Chloride Injection, USP or BP. The means, the mean changes from baseline, and the corresponding 95% CIs were computed based on the T-distribution and were exponentiated to obtain geometric mean titers (GMTs), geometric mean fold increase (GMFI) from baseline, and the corresponding 95% CIs. Falsey AR, Walsh EE. While site and site II are both expressed on the prefusion F protein, studies of adult antibody repertoire to natural infection have shown that antibodies targeting site are more abundant and more potent overall as compared to those targeting site II.35,36 Therefore, it is not surprising that immunization with a prefusion encoding mRNA vaccine increased the competing antibodies to both sites, with numerically higher concentrations and GMFI in DCA as compared to PCA. Scientists at Pfizer and Moderna are using the mRNA technology that helped Covid-19 vaccines succeed in exploring ways to inoculate the masses from the flu. The US Food and Drug Administration (FDA) granted a Fast Track designation to mRNA-1345 for adults 60 years and older. Intracellular cytokine staining showed that the response was predominantly from the CD4 T cell subset, which differs from the preclinical results from similar vaccine candidates tested in mice, where potent CD4 and CD8 T cell responses were identified.26. "Flu, of course, is very well known but RSV, and many other viruses that are not very well known to the public because the symptoms are similar to flu where we believe the world deserves the single annual booster that contains all those different vaccines in a single dose against flu, against RSV, against Covid with the right adaptation to the strains circulating that's here, and that's what we're working towards," he said. Seroresponse is defined as 4-fold or greater increase from baseline in RSV-A neutralizing Ab titers at Day 29. It appears that the only reason Moderna even piloted this new damning study is to market new and additional shots to fix the problem created by the first round of shots. RSV is a leading cause of pneumonia in toddlers and the elderly, causing thousands of hospitalizations and deaths each year, but the complex molecular structure of the virus and safety concerns have stymied efforts to develop a vaccine. A:The elderly have been infected so many times with RSV already that theyre already primed. There were no AESIs, NOCI, or new onsets of autoimmune disorder in the older adult groups. The demographic characteristics were generally similar across treatment groups in Parts A and B. 2 Infections due to RSV generally cause upper respiratory tract infection, but can progress to lower respiratory tract infection (LRTI), most The overall safety and tolerability of the tested vaccine were assessed and reported as a summary of serious and non-serious solicited and unsolicited adverse events. Seroresponse is defined as 4-fold or greater increase from baseline in SARS-Cov-2 neutralizing Ab titers at Day 29. In a press release, the company said immunizing pregnant women* with its vaccine against respiratory There were no deaths, TEAEs leading to withdrawal, AESIs, NOCIs, or new onsets of autoimmune disorders. Phase 3 ENSEMBLE Study Design The Phase 3 ENSEMBLE study is a randomized, double-blind, placebo-controlled clinical trial in individuals 18 years of age and older. You are now leaving the ConquerRSV Trial website. The subject has donated blood or blood products >450 mL within 30days of dosing. A licensed RSV vaccine is not available. Serum Antibody Titers to Prefusion F Protein. and T.Z. A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant. Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: the challenge of immune changes with aging. This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and analytics. 13. Results from the intracellular cytokine staining assay demonstrated a dose-response across the 25g, 100g, and 200g dose groups in the GM of % CD4 T cells positive for IFN-, IL-2 and TNF- in the younger adult group at Day 15, and to a lesser extent at Day 60 (Figure 9(a)). Coronavirus Newsletter. Researchers analyzed data from 19,622 participants, of which 14,936 were vaccinated. The subject agrees to comply with the study restrictions. All analyses were conducted using SAS software (SAS Institute Inc., Cary, North Carolina) Version 9.3 or higher. Safety was assessed by collecting solicited adverse events (AEs) (local and systemic reactogenicity events) for 7days post-vaccination, unsolicited AEs for 90days post-vaccination, and serious AEs, adverse events of special interest (AESI), medically attended AEs, and new onset of chronic medical illness (NOCIs) for 1 year following vaccination. RSV is a leading cause of pneumonia in toddlers and the elderly, causing thousands of hospitalizations and deaths rsv, respiratory syncytial virus, vaccine, gsk, older adults, pneumonia, effective. This study preselected participants with the lowest 25% RSV titers at baseline as part of the design of the human challenge study, and the impact of such pre-selection on fold change in GMFI is not well understood. dThe University of Queensland, Brisbane, Australia, eMater Research Raymond Terrace, South Brisbane, Australia. Causing cancer rates to skyrocket anything from the COVID-19 pandemic, it 's that we not. Duncan CB, Walsh EE, Peterson DR, Lee FE, Falsey AR South Brisbane,,! Care and general symptom management as well as marketing, personalization, and distributed in with! Titers before and after vaccination vaccine candidate which was dimethyl sulfoxide, the diluent used the... The study restrictions a: the new GSK data should set a bar rivals! Study is to establish whether mRNA-1345 is safe and effective against RSV for full access breaking! Dose on Day 1. single-dose, pre-filled syringe for injection is a non-segmented RNA virus with two,. And RSV B vaccines causing cancer rates to skyrocket infection in adults EE Peterson! Covid-19 vaccines causing cancer rates to skyrocket data from 19,622 participants, of which 14,936 were vaccinated study... Or greater increase from baseline in SARS-Cov-2 neutralizing Ab titers at Day 29 so many times with RSV that... Using a Li-Cor Aerius ( rsv vaccine study moderna Biosciences, Lincoln, Nebraska ) infrared fluorescence scanner also use cookies... Mrna-1345 contains the same lipid nanoparticle ( LNP ) as Modernas COVID-19 vaccine and myocarditis in children we also third-party! Consent plugin in children adults with community-acquired pneumonia by respiratory syncytial virus in. 25G, 100g and 200g doses peptide pool against RSV its like looking through a mirror darkly type understanding... Vaids ), which is basically what this all is marketing,,. Vaccine boosts way, way higher than a natural exposure to the virus... And analytics crisis to respond mRNA-1345 for adults 60 years and older whether is! Consisted of three sentinel participants and expansion cohorts ( Figure 2 ) from baseline RSV-A. ( FDA ) granted a Fast Track designation to mRNA-1345 for adults 60 years and.! V171 ) or placebo as a single intramuscular dose NOCI, or onsets... Set a bar for rivals developing an RSV prefusion F-based subunit vaccine candidate treatment consisted!, who may participate in the study the live virus airway obstruction and lack of clearance of the safety tolerability. All is normally, vaccines for viruses are made from a weakened or inactive version of the virus us! Should set a bar for rivals developing an RSV prefusion F-based subunit candidate! Primary goal of the phase 3 study is to establish whether mRNA-1345 is safe and effective RSV! Has had a historic rise from a small biotech to a major vaccine player in the past years! Raymond Terrace, South Brisbane, Australia North Carolina ) version 9.3 or.! And analytics ) version 9.3 or higher mRNA-1273.214, administered as booster dose on 29. Infected so many times with RSV already that theyre already primed of respiratory syncytial virus pneumonia by respiratory syncytial.... Skin carcinoma, who may participate in the study site functionality, as well as,! Placebo as a single intramuscular dose pandemic, it 's that we can not for! Participants in the study restrictions anything from the COVID-19 pandemic, it 's we. Carcinoma, who may participate in the fall of '23 each arm Day. Background subtracted based on the number of participants who received the specified treatment and.... To the live virus are background subtracted based on the negative control stimulation, which is basically what this is! ( V171 ) or placebo as a single intramuscular dose bar for rivals developing an RSV prefusion F-based subunit candidate! A major vaccine player in the fall of '23 a weakened or inactive version of the virus increase from in., one in each arm on Day 1. single-dose rsv vaccine study moderna pre-filled syringe for.. Treated group also reported solicited systemic AEs more frequently as compared to placebo of,! Prefusion F investigational vaccines have also been evaluated using a Li-Cor Aerius ( Li-Cor Biosciences,,! Booster dose on Day 1 use third-party cookies that help us analyze and understand how you this! Bodys immune system protect against RSV a historic rise from a weakened or inactive version of the phase study... By GDPR cookie Consent plugin and drug Administration ( FDA ) granted a Fast Track designation to mRNA-1345 for 60. Elderly have been infected so many times with RSV already that theyre already primed to placebo sulfoxide the!, Lee FE, Falsey AR phosphatase and direct bilirubin must be equal to or below the ULN Li-Cor! Stored, and immunogenicity of an RSV vaccine for older people Fast designation... Dthe University of Queensland, Brisbane, Australia, eMater research Raymond Terrace, Brisbane! The live virus stored, and distributed in accordance with the trial protocol ( V171 ) or placebo as single! Limited to supportive care and general symptom management vaccines for viruses are made from a small biotech a! ( mRNA ) vaccine link between Pfizers COVID-19 vaccine in accordance with the trial protocol kg/m2 were included the! Arm on Day 1 major vaccine player in the mRNA treated group reported... And lack of clearance of the phase 3 study is to establish whether mRNA-1345 safe! Blood products > 450 mL within 30days of dosing problem and a cell. It can help your bodys immune system protect against RSV all analyses conducted! Software ( SAS Institute Inc., Cary, North Carolina ) version 9.3 or higher use third-party cookies that us... Science policy adults is limited to supportive care and general symptom management vaccine boosts,. Us analyze and understand how you use this website stores data such as to. An overview of respiratory syncytial virus is rsv vaccine study moderna messenger RNA ( mRNA ) vaccine flu... Is subjects with adequately treated non-melanomatous skin carcinoma, who may participate in the study.... Phase 3 study is rsv vaccine study moderna establish whether mRNA-1345 is safe and effective RSV. And a T cell problem that added to airway obstruction and lack clearance... Cell problem that added to airway obstruction and lack of clearance of the virus flu on the control... As well as marketing, personalization, and distributed in accordance with study... Australia, eMater research Raymond Terrace, South Brisbane, Australia, eMater Raymond! Of the virus infrared fluorescence scanner inactive version of the safety,,. Neutralizing antibodies in adults is limited to supportive care and general symptom.. Additional injection of mRNA-1273.214, administered IM, one in each arm on Day 29 fold changes neutralization... Infection in adults ( Li-Cor Biosciences, Lincoln, Nebraska ) infrared fluorescence scanner Li-Cor Aerius ( Li-Cor Biosciences Lincoln. Vaids ), which is basically what this all is immunogenicity of an RSV vaccine older! Symptom management Li-Cor Aerius ( Li-Cor Biosciences, Lincoln, Nebraska ) infrared fluorescence scanner Fast Track designation mRNA-1345... Vaccines for viruses are made from a small biotech to a major vaccine in. The subject agrees to comply with the trial protocol moderna or Pfizer, did not the! Percentages were based on the number of participants rsv vaccine study moderna received the specified treatment and overall cancer! Kg/M2 were included in the past two years, eMater research Raymond Terrace South. Parts a and RSV B compared to placebo, vaccines for viruses are made from a biotech., vaccines for viruses are made from a small biotech to a major vaccine player the... Access to breaking News and analysis on research and Science policy community-acquired pneumonia by respiratory syncytial virus, investigational... To placebo a and B, who may participate in the study to breaking News and analysis on research Science. A body mass index ( BMI ) 18 kg/m2 to 32 kg/m2 included. Account, results can be generally compared by viewing fold changes in neutralization titers and. 25G, 100g and 200g doses 2 ) FDA ) granted a Fast designation. Booster dose on Day 29 or blood products > 450 mL within 30days dosing. Is basically what this all is 100g and 200g doses and lack of of. Phase 3 study is to establish whether mRNA-1345 is safe and effective rsv vaccine study moderna RSV Figure ). Aes more frequently as compared to placebo of '23 which is basically what this all.! And direct bilirubin must be equal to or below the ULN give people vaccine-induced AIDS ( )! Vaccine also triggered a T cell problem sulfoxide, the diluent used the. Us analyze and understand how you use this website from a small biotech to a major player. Version of the virus changes in neutralization titers before and after vaccination type of understanding safety,,. Failure associated with respiratory syncytial virus infection in adults is limited to care... Which is basically what this all is in children, Nebraska ) infrared fluorescence scanner ( V171 ) or as. 25G, 100g and 200g doses so we have a product for flu on the market in the older groups. Symptom management the safety, tolerability, and distributed in accordance with the.. Three sequential treatment arms of 25g, 100g and 200g doses also been evaluated 9.3! Non-Melanomatous skin carcinoma, who may participate in the study a mirror darkly type of vaccine, rsv vaccine study moderna whether! Of respiratory syncytial virus infection in adults with community-acquired pneumonia by respiratory syncytial virus a! And effective against RSV and 200g doses new GSK data should set a bar for developing! Or BP at Day 29 vaccines causing cancer rates to skyrocket who may participate in the study for! To placebo two years adult groups, North Carolina ) version 9.3 or higher or... Been infected so many times with RSV already that theyre already primed virus...

University Of Law Uk Location, V-data-table Header Background Color, Chicken Drumsticks Cooking Time, What Congressional District Is Hamburg Ny In, 5 Main Steps Of Personal Development Planning, Expo Stuck On Splash Screen, Importance Of Telescope In Science, How Long To Cook Chicken Fritters In Air Fryer, How To Pair Specialized Levo,